Head-to-head · WeighScore
Effecty vs Ro
The verdict
Effecty takes it — 84/100 to 78/100.
Effecty grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mid-market pricing offset by brand-name access and LegitScript verification, all 50 states.
Both are editorial reviews with no commercial relationship.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Effecty | Ro |
|---|---|---|
| WeighScore | 84/100 | 78/100 |
| Grade | B | C+ |
| Scorecard rank | #10 | #24 |
| Semaglutide | $160/mo | Not disclosed |
| Tirzepatide | $240/mo | Not disclosed |
| Coverage | All 50 states | Multi-state |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Yes |
| Relationship | Editorial | Editorial |
Graded #10 · B
Strengths
- Brand-name access
- LegitScript-verified, all 50 states
- Both molecules
Where it loses points
- Higher pricing ($160/$240)
- Injection-only
- Not a value leader
Graded #24 · C+
Strengths
- Brand-name access + insurance support
- Oral options
- Well-funded platform
Where it loses points
- Does not disclose compounded pricing up front
- Premium positioning
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 25 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.